NCT02829931 is a Phase 1 clinical trial of Hypofractionated Stereotactic Irradiation in Malignant Glioma, sponsored by H. Lee Moffitt Cancer Center and Research Institute.

Who is sponsoring NCT02829931?

NCT02829931 is sponsored by H. Lee Moffitt Cancer Center and Research Institute.

What drugs are being tested in NCT02829931?

Interventions in NCT02829931: Hypofractionated Stereotactic Irradiation, Nivolumab, Bevacizumab, Ipilimumab.

What condition does NCT02829931 study?

NCT02829931 studies Malignant Glioma.

Is NCT02829931 still recruiting?

NCT02829931 is currently completed. Last updated 19 January 2023.

Last reviewed 2023-01-19 · How we verify

NCT02829931

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Hypofractionated Stereotactic Irradiation With Nivolumab, Ipilimumab and Bevacizumab in Patients With Recurrent High Grade Gliomas

Completed Phase 1 Last updated 19 January 2023

What this trial tests

Phase 1 trial testing Hypofractionated Stereotactic Irradiation in Malignant Glioma in 33 participants. Completed in 22 November 2022.

Timeline

22 August 2016

Primary endpoint
11 August 2021

22 November 2022

Quick facts

Lead sponsor	H. Lee Moffitt Cancer Center and Research Institute
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	33
Start date	22 August 2016
Primary completion	11 August 2021
Estimated completion	22 November 2022
Sites	2 locations across United States

Drugs / interventions tested

Hypofractionated Stereotactic Irradiation
Nivolumab (nivolumab) — full drug profile →
Bevacizumab (Bevacizumab-Bvzr) — full drug profile →
Ipilimumab — full drug profile →

Conditions studied

Malignant Glioma — all drugs for Malignant Glioma →

Sponsor

H. Lee Moffitt Cancer Center and Research Institute

Who can join

18 and older, any sex, with Malignant Glioma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The main purpose of this study is to evaluate the safety, and tolerability of nivolumab, ipilimumab, and bevacizumab given in combination with hypofractionated stereotactic re-irradiation of recurrent high grade gliomas.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Recurrent glioma clinical trial, CheckMate-143: the game is not over yet.
Filley AC, Henriquez M, Dey M. · · 2017 · cited 284× · PMID 29207684 · DOI 10.18632/oncotarget.21586
Current State of Immunotherapy for Treatment of Glioblastoma.
McGranahan T, Therkelsen KE, Ahmad S, Nagpal S. · · 2019 · cited 209× · PMID 30790064 · DOI 10.1007/s11864-019-0619-4
PD-L1/PD-1 Axis in Glioblastoma Multiforme.
Litak J, Mazurek M, Grochowski C, Kamieniak P, et al · · 2019 · cited 152× · PMID 31661771 · DOI 10.3390/ijms20215347
Advances in Glioblastoma Therapy: An Update on Current Approaches.
Angom RS, Nakka NMR, Bhattacharya S. · · 2023 · cited 140× · PMID 38002496 · DOI 10.3390/brainsci13111536
Immune Checkpoint Inhibitors in Human Glioma Microenvironment.
Ghouzlani A, Kandoussi S, Tall M, Reddy KP, et al · · 2021 · cited 119× · PMID 34305910 · DOI 10.3389/fimmu.2021.679425
PD-1 Inhibitors: Do they have a Future in the Treatment of Glioblastoma?
Khasraw M, Reardon DA, Weller M, Sampson JH. · · 2020 · cited 110× · PMID 32527943 · DOI 10.1158/1078-0432.ccr-20-1135
Hypofractionated stereotactic re-irradiation with pembrolizumab and bevacizumab in patients with recurrent high-grade gliomas: results from a phase I study.
Sahebjam S, Forsyth PA, Tran ND, Arrington JA, et al · · 2021 · cited 91× · PMID 33173935 · DOI 10.1093/neuonc/noaa260
Immunotherapy in Glioblastoma: Current Shortcomings and Future Perspectives.
Weenink B, French PJ, Sillevis Smitt PAE, Debets R, et al · · 2020 · cited 71× · PMID 32235752 · DOI 10.3390/cancers12030751

Verify or expand the search:

Other recruiting trials for Malignant Glioma

Currently open trials in the same condition.

NCT07480941 — Dual-Targeting CAR-NK Cells for Recurrent/Progressive Glioblastoma and High-Grade Glioma · Phase 1 · recruiting
NCT07447531 — T2 Star Magnetic Resonance Imaging and Biomarker Blood Testing to Predict the Change and Progress of Malignant Gliomas · NA · recruiting
NCT06470711 — Mapping of Electrical Properties in the Brain · recruiting
NCT05717153 — Intratumoral Extracellular Metabolic Impact of DFMO and AMXT 1501 in Patients With Diffuse or High Grade Glioma · EARLY_PHASE1 · recruiting
NCT05030298 — Preoperative Radiosurgery for the Treatment of High Grade Glioma, NeoGlioma Trial · Phase 1 · recruiting

Other H. Lee Moffitt Cancer Center and Research Institute trials

Trials by the same sponsor.

NCT05041335 — Wet Heparinized Suction for Abdominal Cancer · NA · not yet recruiting
NCT07222995 — Hybrid Effectiveness-Implementation Trial to Integrate Precision Skin Cancer Risk Feedback in FQHCs · NA · recruiting
NCT06047977 — Tumor Infiltrating Lymphocyte Therapy for Pediatric High Risk Solid Tumors · Phase 1 · recruiting
NCT06121180 — Study of Cemiplimab Plus Ziv-Aflibercept for Subjects With Metastatic Uveal Melanoma · Phase 2 · recruiting
NCT06193486 — Autologous Gamma Delta T Cells to Target Prostate Stem Cell Antigen in mCRPC · Phase 1 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02829931 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by H. Lee Moffitt Cancer Center and Research Institute
Last refreshed: 19 January 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02829931.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing